Studies conducted in Peru and at international level prove the effectiveness of the vaccine from Chinese laboratory Sinopharm to reduce COVID-19-related hospitalizations and deaths, Health Minister Oscar Ugarte reported on Wednesday.
For its part, the study by the National Center for Epidemiology, Prevention and Disease Control (CDC) has determined that the Sinopharm vaccine offers 94% protection against the risk of death from this virus.
"Studies carried out by the
National Health Institute (INS) and the National Center for Epidemiology, Prevention and Disease Control (CDC) show a protection of 90% and 94% against the risk of dying from COVID-19," the health sector's head emphasized.
Third dose
"Let's remember that the immunization process around the world began at the end of last year, so specialists have not had enough time to verify it," he added.
However, the Cabinet member affirmed that Peruvian health authorities consider this possibility. Therefore, the Government has acquired doses in a much higher quantity.
For this reason, the minister explained that there are different options on what science can determine.
Another alternative would be to purchase products that laboratories have been studying and developing on a trial basis.
Some organizations, such as the Peruvian College of Physicians (CMP), are raising about the inoculation of an additional Pfizer dose to those who have already been vaccinated with Sinopharm.
"We have communicated with the laboratory and with the experts of our Ethics Committee, and they do not recommend this method because this is not proven by science," he concluded.